Fort Washington Investment Advisors Inc. OH Acquires 14,301 Shares of Eli Lilly and Company $LLY

Fort Washington Investment Advisors Inc. OH raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 41.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,915 shares of the company’s stock after buying an additional 14,301 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Eli Lilly and Company were worth $37,322,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC raised its stake in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares in the last quarter. EP Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company by 103.7% in the 1st quarter. EP Wealth Advisors LLC now owns 69,144 shares of the company’s stock worth $57,106,000 after buying an additional 35,207 shares during the last quarter. Dark Forest Capital Management LP increased its holdings in shares of Eli Lilly and Company by 715.8% in the 1st quarter. Dark Forest Capital Management LP now owns 5,425 shares of the company’s stock worth $4,481,000 after buying an additional 4,760 shares during the last quarter. Finally, Southpoint Capital Advisors LP purchased a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $49,555,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on LLY. Leerink Partnrs upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday, December 19th. CICC Research upped their price objective on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Loop Capital set a $950.00 price objective on Eli Lilly and Company in a report on Monday, November 10th. Finally, National Bankshares set a $1,286.00 target price on Eli Lilly and Company in a research report on Monday, December 1st. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,155.36.

Eli Lilly and Company Trading Up 0.1%

NYSE LLY opened at $1,079.84 on Wednesday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The stock has a 50-day moving average of $997.74 and a 200-day moving average of $845.33. The firm has a market cap of $1.02 trillion, a PE ratio of 52.83, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the company earned $1.18 EPS. Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.